478162-80-0

Upstream product

• 99-93-4 4-Hydroxyacetophenone 
• 187532-78-1 4-(2,6-difluorobenzyloxy)acetophenone 
• 478163-34-7 3-(2,6-dimethylbenzyloxy)acetophenone 
• 105-36-2 ethyl bromoacetate 
• 478162-60-6 ethyl 4-(4-(2,6-difluorobenzyloxyl)phenyl)-4-oxobutyrate 

Downstream Products

• 478162-78-6 4-(3-(2,6-dimethylbenzyloxy)phenyl)-4-oxobutyric acid 
• 478163-46-1 ethyl 4-(3-(2,6-dimethylbenzyloxy)phenyl)-4-oxo-3-bromo-butyrate 
• 1389396-35-3 ethyl 4-(3-(2,6-dimethylbenzyloxy)phenyl)-4-hydroxy-butyrate 
• 1389396-36-4 ethyl 4-(3-(2,6-dimethylbenzyloxy)phenyl)-4-bromo-butyrate 
• 478162-93-5 4-(3-(2,6-dimethylbenzyloxy)phenyl)-4-oxobutyramide 
• 478162-88-8 4-(3-(2,6-dimethylbenzyloxy)phenyl)butyric acid 
• 478162-83-3 4-(3-(2,6-dimethylbenzyloxy)phenyl)-4-oxobutyric acid potassium salt 
• 478162-81-1 4-(3-(2,6-dimethylbenzyloxy)phenyl)-4-oxobutyric acid sodium salt 

Relevant academic research and scientific papers

Compounds for the treatment of metabolic disorders

Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

SYNTHESIS OF 4-[3-(2,6-DIMETHYLBENZYLOXY)PHENYL]-4-OXOBUTANOIC ACID

The compound 4-[3-(2,6-Dimethylbenzyloxy)phenyl]-4-oxobutanoic acid (DPA) is synthesized from 1-[3-(2,6-Dimethylbenzyloxy)-phenγl]-ethanone (DPE) via the intermediate 4-[3-(2,6-Dimethylbenzyloxy)phenyl]-4-oxobulanoic acid ethyl ester (DPAE).

Compounds for the treatment of metabolic disorders

Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.